Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments
Cash runway extended to January 2019 SOLANA BEACH, Calif. , March 26, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that it has amended the Company’s agreement with
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ dose Announced discovery of sex-based pharmacokinetic differences for Gimoti™ Met with FDA regarding NDA women-only filing strategy and post-marketing plans 505(b)(2) NDA submission planned for
View HTML
Toggle Summary Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences
SOLANA BEACH, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that Dave Gonyer , President and Chief Executive Officer, will present at the 30 th Annual Roth
View HTML
Toggle Summary FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application
Cash runway updated into October 2018 SOLANA BEACH, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the U.S.
View HTML
Toggle Summary Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results
SOLANA BEACH, Calif. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the fourth quarter and full year ended December 31,
View HTML
Toggle Summary Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™
Recent Pre-NDA Meeting Provided Guidance on Female Only NDA Filing Strategy and Post-Approval Safety Study SOLANA BEACH, Calif. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2017 Results and Highlights
Announced positive topline results from comparative exposure pharmacokinetic (PK) trial for Gimoti™ 505(b)(2) New Drug Application (NDA) submission on track for Q1 2018 filing Partnered with the Patheon division of Thermo Fisher Scientific Inc. as a commercial manufacturing partner for Gimoti
View HTML
Toggle Summary Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific
SOLANA BEACH, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of the Patheon division of Thermo Fisher Scientific, Inc., as the commercial
View HTML
Toggle Summary Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results
SOLANA BEACH, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the third quarter ended September 30, 2017 on
View HTML
Toggle Summary Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti™
Call Scheduled for October 31st at 9am ET
View HTML